Biogen Idec’s TECFIDERA™ approved in US as a first-line oral treatment for multiple sclerosis
27 March 2013 | By Biogen Idec
The U.S. FDA has approved TECFIDERA™...
List view / Grid view
27 March 2013 | By Biogen Idec
The U.S. FDA has approved TECFIDERA™...
26 March 2013 | By Ogilvy HealthPR London
“We are pleased with the promising results..."
26 March 2013 | By Gilead Sciences
Gilead Sciences provided an update on ION-1...
26 March 2013 | By Novartis
Latest global patient-use data...
26 March 2013 | By Boehringer Ingelheim
A new perspective from the U.S. FDA...
25 March 2013 | By Pfizer
“RA is a serious and disabling disease and there is a need for new treatment options..."
25 March 2013 | By GlaxoSmithKline
GSK received a Complete Response letter...
25 March 2013 | By Daiichi Sankyo
Approval to manufacture and market the osteoporosis treatment...
25 March 2013 | By Sanofi
Creation of a new state-of-the-art industrial platform at Genzyme’s unit in Lyon...
22 March 2013 | By Biosector 2
Positive opinion on the marketing authorization application for Iclusig™...
22 March 2013 | By GCI Health
European Commission decision anticipated in second quarter of 2013...
22 March 2013 | By Gilead Sciences
Stribild® a once-daily integrase inhibitor-based single tablet regimen for the treatment of HIV-1 infection...
21 March 2013 | By PARADIGM COMMUNICATIONS
TEVA and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study...
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
21 March 2013 | By Just:: Health PR
2013 Patient Group Bursary Scheme launched...